share_log

Aegis Capital Initiates Coverage On Sunshine Biopharma With Buy Rating, Announces Price Target of $2.6

Benzinga ·  Aug 7, 2023 12:02

Aegis Capital analyst David Bouchey initiates coverage on Sunshine Biopharma (NASDAQ:SBFM) with a Buy rating and announces Price Target of $2.6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment